Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Dec 22:S0360-3016(20)34356-X. doi: 10.1016/j.ijrobp.2020.09.054

Table 3.

Selected studies analyzing factors associated with late sexual side effect

Study n Treatment details Med. f/u (yrs) Sexual endpoint Dosimetric factors associated* with worse sexual outcomes Non-dosimetric factors associated* with worse sexual outcomes
Wiegner 201036 (Stanford) 32 (no ADT) 36.25 Gy (5 fx), QD/QOD 3.0 EPIC QOL 20M impotency: 61% (23% if potent at baseline) (PB not associated)

  • Higher age
Obayomi-Davies 201337 (Georgetown) 97 (Potent at baseline, no ADT) 35–36.25 Gy (5 fx), QOD 2.7 EPIC QOL
2Y impotency: 45.6%		 (PB not associated)

  • Charlson Comorbidity Index ≥ 1
Elias 201422 (Sunnybrook) 84 (4% ADT) 35 Gy (5 fx), QW 4.2 EPIC QOL
MID: 37.5%

  • PB V20Gy > 40%

  • PB V35Gy > 4%
Dess 201838 (Georgetown) 373 (no ADT) 35–36.25 Gy (5 fx), QOD 4.7 EPIC QOL 2Y impotency: 66% (43% if potent at baseline) (PB not analyzed)

  • Higher age

  • Higher body mass index

  • Diabetes

  • Hypertension

  • Coronary artery disease

Abbreviations: ADT; androgen deprivation therapy, QW; every week, QOD; every other day, QD; every day, MID; minimally important difference, PB; penile bulb

*

Included if reported as trend or significant on univariate or multivariate analysis